Valneva SE VALN 深 沪
等待开盘 08-26 09:30:00 美东时间
9.43
-2.210
-18.99%
华盛通- 最 高9.50
- 今 开9.12
- 成交量 34.98万股
- 最 低 9.01
- 昨 收 11.64
- 总市值 8.02亿
- 52周最高 12.25
- 市盈率 静 --
- 换手率 0.41%
- 52周最低 3.62
- 委 比 -64.30%
- 总股本 8503.19万
- 历史最高 67.84
- 量 比 4.32
- 振 幅 4.21%
- 历史最低 3.62
- 每 手 1
- 风险率 1.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多欧洲股市下跌 风能板块遭美国监管阻力打击
欧洲股市下跌，风能相关股票领跌，此前Orsted A/S在美国的一个项目被叫停。法国股市则因总理贝鲁呼吁进行信任投票而走低。 斯托克欧洲600指数收盘下...
今天 00:37
Valneva shares are trading lower after the FDA suspended the license for IXCHIQ.
Valneva shares are trading lower after the FDA suspended the license for IXCHIQ.
08-25 21:04
美FDA意外叫停一款基孔肯雅热疫苗 法国制药商股价崩跌超两成
①法国生物技术公司瓦尔内瓦欧股跌超20%，因美FDA暂停其基孔肯雅热疫苗IXCHIQ的使用，令市场意外； ②瓦尔内瓦正在对严重不良事件案例进行调查，并表示将继续向其他批准该疫苗的国家供应。今年上半年，IXCHIQ为公司带来了750万欧元的销售额。
08-25 19:23
Valneva Faces FDA Suspension of Chikungunya Vaccine License
The latest update is out from Valneva ( ($VALN) ). On August 25, 2025, Valneva ...
08-25 18:47
Biggest stock movers Monday: NIO, VALN, and more
Stock futures edged lower Monday morning as Wall Street kicked off the final trading week of August with focus on Nvidia’s upcoming earnings. Here are some of Monday's biggest stock movers: Biggest st...
08-25 17:00
Valneva suspended from marketing chikungunya shot in U.S. over safety concerns
The U.S. Food and Drug Administration (FDA) late Friday announced that it has suspended the marketing application granted for French biotech Valneva’s (NASDAQ:VALN) chikungunya vaccine Ixchiq due to s...
08-23 19:04
HC Wainwright & Co. Assumes Valneva at Buy, Announces Price Target of $18
HC Wainwright & Co. analyst Brandon Folkes assumes Valneva (NASDAQ:VALN) with a Buy rating and announces Price Target of $18.
08-19 19:10
Valneva’s Chikungunya Vaccine IXCHIQ® Gains Health Canada Approval
Valneva ( ($VALN) ) has issued an announcement. On August 18, 2025, Valneva SE ...
08-18 22:07
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Valneva Reaffirms Outlook: 2025 Sales Revenue Projected At €170M-€180M, Total Revenue To Reach €180M-€190M; R&D Investments Of €90M-€100M
Financial OutlookThe Company confirms the following guidance for fiscal year 2025:Product sales expected to grow to €170-180 million, driving positive cash flow for the commercial businessTotal revenues expected to reach
08-12 13:24
